MedTrace Logo

Iressa/Docetaxel in Non-Small-Cell Lung Cancer

NCT00048087 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2012-07-31

No results posted yet for this study

Summary

Patients will receive 250 mg Iressa by mouth daily each day while on this study. Patients will also receive docetaxel 30 mg/m2 by by vein (IV) on day 1 weekly for the first 3 weeks of each course of therapy. A course of therapy is 4 weeks. Patients will not receive docetaxel during week 4. A maximum of 8 full cycles of docetaxel plus Iressa are planned. Patients may continue on daily Iressa until progressive disease and/or unacceptable toxicity.

Conditions

Interventions

DRUG

ZD1839

250 mg by mouth daily each day for 4 weeks.

DRUG

Docetaxel

30 mg/m2 by IV on day 1 weekly for the first 3 weeks of each 4 week course.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Aventis Pharmaceuticals

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Edward S. Kim, MD, BS · UT MD Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-08-31
Primary Completion
2003-07-31
Completion
2003-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00048087 on ClinicalTrials.gov